Note 7 - Subsequent Event	6 Months Ended
Jun. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	Note 7 — Subsequent Events On July 10, 2018, the Company terminated its Agreement and Plan of Merger dated as of January 21, 2018 ( the “Merger Agreement”) with Idera Pharmaceuticals, Inc. (“Idera”). The merger Agreement was terminated following the July 10, 2018 special meeting of the stockholders of the Company at which time the proposal to adopt the Merger Agreement was not approved by the holders of a majority of the Company’s issued and outstanding shares of common stock. Pursuant to the terms of the Merger Agreement, the Company paid a $6,000 expense reimbursement amount to Idera in July 2018. On July 20, 2018, the Company, together with its consolidated subsidiary, MDCP, LLC (collectively, the “Borrowers”), entered into a $30,000 secured loan facility with MidCap Financial, a Delaware statutory trust, as administrative agent and lender (“MidCap”), pursuant to the terms and conditions of that certain Amended and Restated Credit and Security Agreement, dated as of July 20, 2018 ( the “Amended and Restated Senior Credit Facility”), among the Borrowers, MidCap, and the lenders party thereto from time to time. The Amended and Restated Senior Credit Facility refinances and replaces the Senior Credit Facility dated as of September 23, 2016. The Amended and Restated Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which shall not be less than 0.5% ) plus 8%. The Amended and Restated Senior Credit Facility includes an interest-only payment period through July 2019 and scheduled monthly principal and interest payments for the subsequent 30 months. The Company used a portion of the proceeds of the Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Senior Credit Facility and the remainder will be used for general corporate purposes. On August 6, 2018, the Company completed an underwritten public offering of 10,454,546 shares of its common stock, offered at a price to the public of $5.50 per share, including shares issued pursuant to the underwriters’ 30 -day option to purchase additional shares, which was exercised in full. The net proceeds from this offering to the Company were approximately $53,400 after deducting underwriting discounts and commissions and estimated offering expenses.

Note

— Subsequent Events

July 10, 2018,

the Company terminated its Agreement and Plan of Merger dated as of

January 21, 2018 (

the “Merger Agreement”) with Idera Pharmaceuticals, Inc. (“Idera”). The merger Agreement was terminated following the

July 10, 2018

special meeting of the stockholders of the Company at which time the proposal to adopt the Merger Agreement was

not

approved by the holders of a majority of the Company’s issued and outstanding shares of common stock. Pursuant to the terms of the Merger Agreement, the Company paid a

$6,000

expense reimbursement amount to Idera in

July 2018.

July 20, 2018,

the Company, together with its consolidated subsidiary, MDCP, LLC (collectively, the “Borrowers”), entered into a

$30,000

secured loan facility with MidCap Financial, a Delaware statutory trust, as administrative agent and lender (“MidCap”), pursuant to the terms and conditions of that certain Amended and Restated Credit and Security Agreement, dated as of

July 20, 2018 (

the “Amended and Restated Senior Credit Facility”), among the Borrowers, MidCap, and the lenders party thereto from time to time. The Amended and Restated Senior Credit Facility refinances and replaces the Senior Credit Facility dated as of

September 23, 2016.

The Amended and Restated Senior Credit Facility was fully funded at closing and bears a variable interest rate of LIBOR (which shall

not

be less than

0.5%

) plus

8%.

The Amended and Restated Senior Credit Facility includes an interest-only payment period through

July 2019

and scheduled monthly principal and interest payments for the subsequent

months. The Company used a portion of the proceeds of the Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Senior Credit Facility and the remainder will be used for general corporate purposes.

August 6, 2018,

the Company completed an underwritten public offering of

10,454,546

shares of its common stock, offered at a price to the public of

$5.50

per share, including shares issued pursuant to the underwriters’

-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering to the Company were approximately

$53,400

after deducting underwriting discounts and commissions and estimated offering expenses.